By Rajiv Rao ZDNet.com
The last two months have been busy ones for the marijuana community. Most recently, the Drug Enforcement Administration (DEA) declined to loosen restrictions on medical marijuana, and kept the drug classified in the same ‘Schedule 1’ category as LSD and heroin.
There was much handwringing before and after the decision was handed out over the pros and cons about marijuana’s possible re-scheduling. Some thought that if it did get bumped down into Schedule 2 — a more benign category of addictive substances such as methadone and fentanyl — it would make the entire industry vulnerable to a whole new set of potentially crippling regulations. Others thought that it would finally de-criminalize the substance and free it from the yoke of the federal government.